The aim of this study was to evaluate the efficacy of pimecrolimus oil-based eye drops in alleviating the clinical signs of keratoconjunctivitis
sicca (KCS) in dogs and to compare the efficacy with that of cyclosporine A (CsA) ointment. An open-label, multicenter study
enrolling 44 dogs previously untreated with CsA was conducted. Dogs were randomly assigned to a treatment group and medicated twice
daily for 8 weeks. After that time the mean increase (±SEM) in the Schirmer tear test was 9.2 ± 1.6 mm/min in the pimecrolimus group
and 5.8 ± 1.1 mm/min in the CsA group (P = 0.085). The improvement in clinical signs of inflammation in eyes treated with pimecrolimus
was significantly greater than in eyes treated with CsA (P = 0.02). The results show that 1% pimecrolimus oily eye drops are as safe
as and more effective than CsA ointment in controlling KCS in dogs.